licensing

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Madrigal builds in MASH with $4.4bn+ Ribo alliance

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.

Boehringer bets up to $500m on Sitryx immunology programme

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

Astellas bets on Vir cancer drug, and other licensing deals

Madrigal builds in MASH with $4.4bn+ Ribo alliance

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

licensing

Editor's Picks